What's Happening?
Bracco Imaging, a global leader in diagnostic imaging, has launched an Early Access Program for its new BubbleGen technology, aimed at enhancing cell therapy processes. The BubbleGen technology utilizes buoyant microbubbles for cell separation and activation,
offering an alternative to traditional magnetic bead-based methods. This innovation is designed to streamline cell therapy manufacturing by enabling one-step cell separation and activation without magnetic residuals. The technology is particularly beneficial for targeting specific cell subtypes, including rare populations. Bracco is showcasing this technology at the International Society for Cell & Gene Therapy (ISCT) 2026 conference in Dublin, Ireland. The program allows academic and industry researchers to evaluate the technology's performance and provide feedback to guide future product development.
Why It's Important?
The introduction of BubbleGen technology by Bracco Imaging represents a significant advancement in the field of cell therapy. By providing a more efficient and flexible method for cell separation and activation, this technology could potentially enhance the development and production of cell-based therapies, such as CAR T-cell therapies. This innovation is crucial as it addresses the limitations of current methods, which often involve complex and time-consuming processes. The ability to target specific cell subtypes and improve sample purity could lead to more effective treatments and better patient outcomes. Additionally, the Early Access Program allows researchers to tailor the technology to their specific needs, fostering innovation and collaboration in the field.
What's Next?
As the BubbleGen Early Access Program progresses, participating researchers will evaluate the technology's application across various cell therapy processes. Their feedback will be instrumental in refining the technology and expanding its capabilities. Bracco Imaging plans to work closely with these teams to support experimental design and troubleshoot challenges, ensuring the technology meets the diverse needs of the cell therapy industry. The insights gained from this program could lead to further enhancements and broader adoption of microbubble-based cell selection in clinical and commercial settings.
